AC3056 Uses, Dosage, Side Effects and more
AC3056 is a non-peptide antioxidant that acts as an inhibitor of vascular cell adhesion molecule expression originally developed by Aventis Pharmaceuticals. It as since been acquired by Amylin Pharmaceuticals and has completed phase I trials.
Oral administration of AC3056 results in dose-dependent antioxidant activity and was well tolerated. In 2002, positive results were reported from a phase I trial. In the double-blind, placebo-controlled, crossover trial, 14 healthy subjects received an oral formulation of AC3056 in a dose-escalating manner. Results demonstrated dose-dependent increases in blood levels of AC3056, as well as dose-dependent increases in serum antioxidant activity. The drug was well tolerated with no safety concerns.
| Attribute | Details |
|---|---|
| Trade Name | AC3056 |
| Generic | AC3056 |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
For the treatment of atherosclerosis and other conditions related to the obstruction of blood vessels.
Elimination Route
Absorbed following oral administration.
